NYC-based Precision Neuroscience, co-founded by a Neuralink co-founder to create a less invasive brain implant to track diseases, raised a $41M Series B
Sarah McBride / Bloomberg :
Context & Ripple Effects
At the time of this raise, Precision Neuroscience was an early-stage bet on a different implant philosophy than its co-founder's former company: a thin device of surface electrodes rather than Neuralink's penetrating approach, aimed at reading brain signals to track disease. The company had just been founded and needed capital to move toward human testing.
The arc since then validates the thesis this round funded: Precision ran its first in-human study mapping brain signals, scaled up with a $102M Series C at a ~$500M valuation, and won FDA clearance in March 2025 for its 1,024-electrode implant — while rival Synchron, which threads its implant through the circulatory system to avoid open-brain surgery entirely, raised $200M at nearly $1B.
First-order effects
- The $41M gives Precision Neuroscience runway to advance its less invasive electrode array toward the human trials it later claimed, directly funding a disease-tracking use case distinct from Neuralink's focus.
- Neuralink gains a well-funded competitor founded by one of its own co-founders, splitting talent and investor attention within the US brain-computer interface field.
Second-order effects
- Precision's progress pushed capital toward the broader 'less invasive' camp: Synchron's circulatory-delivery implant and Barcelona-based Inbrain's graphene device each drew large follow-on rounds, making minimally invasive access the sector's dominant fundraising pitch.
- Neuralink responded on scale rather than invasiveness, with Musk outlining high-volume device production and near-automated implant surgery targeted for 2026 — competing on manufacturing throughput while rivals compete on surgical risk.
Third-order effects
- If the pattern holds, the BCI industry structurally splits into two tracks — penetrating electrodes versus surface or vascular access — with regulators like the FDA effectively picking winners through clearance decisions such as Precision's.
- Disease monitoring could become the commercial beachhead for implants before consumer applications, since diagnostic use cases clear regulatory paths faster and justify the capital intensity these rounds represent.
The trend: Brain-computer interface funding is consolidating around less invasive implant designs — surface electrodes, vascular delivery, novel materials — as the credible counter-thesis to Neuralink's penetrating-electrode approach.